ABSTRACT
Background There is a need for better prediction of disease severity in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Soluble angiotensin-converting enzyme 2 (sACE2) arises from shedding of membrane ACE2 (mACE2) that is known to be a receptor for the spike protein of SARS-CoV-2; however, its value as a biomarker for disease severity is unknown. This study evaluated the predictive value of sACE2 in the context of other known biomarkers of inflammation and tissue damage (C-reactive protein [CRP], growth/differentiation factor-15 [GDF-15], interleukin-6 [IL-6], and soluble fms-like tyrosine kinase-1 [sFlt-1]) in patients with and without SARS-CoV-2 with different clinical outcomes.
Methods For univariate analyses, median differences between biomarker levels were calculated for the following patient groups classified according to clinical outcome: reverse transcription polymerase chain reaction (RT-PCR)-confirmed SARS-CoV-2 positive (Groups 1–4); RT-PCR-confirmed SARS-CoV-2 negative following previous SARS-CoV-2 infection (Groups 5 and 6); and RT-PCR-confirmed SARS-CoV-2 negative controls (Group 7).
Results Median levels of CRP, GDF-15, IL-6, and sFlt-1 were significantly higher in patients with SARS-CoV-2 who were admitted to hospital compared with patients who were discharged (all p<0.001), whereas levels of sACE2 were significantly lower (p<0.001). Receiver operating characteristic curve analysis of sACE2 provided cut-offs for the prediction of hospital admission of ≤0.05 ng/mL (positive predictive value: 89.1%) and ≥0.42 ng/mL (negative predictive value: 84.0%).
Conclusion These findings support further investigation of sACE2, either as a single biomarker or as part of a panel, to predict hospitalisation risk and disease severity in patients infected with SARS-CoV-2.
HIGHLIGHTS Noelia Diaz Troyano: Noy-Lee-ah Dee-az Tro-yah-no
Better prediction of disease severity in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed. We measured soluble angiotensin-converting enzyme 2 (soluble ACE2) and other biomarkers of inflammation and tissue damage in patients recruited from Vall d’Hebron University Hospital, with and without SARS-CoV-2 and with different clinical outcomes. Levels of soluble ACE2 were significantly lower in patients with SARS-CoV-2 who had the most severe clinical outcome in all comparisons. These findings support a protective role for soluble ACE2 in SARS-CoV-2 infection and warrant further investigation of soluble ACE2 as a biomarker for disease severity in patients with SARS-CoV-2.
Competing Interest Statement
Noelia Diaz Troyano: no competing interests Pablo Gabriel Medina: no competing interests Stephen Weber: employee of Roche Diagnostics GmbH (Penzberg, Germany) and holds shares in F. Hoffmann-La Roche Ltd Martin Klammer: employee of Roche Diagnostics GmbH (Penzberg, Germany) and holds shares in F. Hoffmann-La Roche Ltd Raquel Barquin-DelPino: no competing interests Laura Castillo-Ribelles: no competing interests Angels Esteban: no competing interests Manuel Hernández-González: no competing interests Roser Ferrer-Costa: no competing interests Tomas Pumarola: no competing interests Francisco Rodriguez Frias: no competing interests
Funding Statement
This study was funded by Roche Diagnostics International Ltd (Rotkreuz, Switzerland) and Vall d'Hebron University Hospital (Barcelona, Spain) public funds.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the principles of the Declaration of Helsinki and received approval (reference: PR [AG] 577/2020) from the Research Ethics Committee for Drug Research of the Vall d'Hebron University Hospital (Barcelona, Spain). Patient-level data were processed in accordance with Regulation (EU) 2016/679 of the European Parliament on Data Protection. An exemption from obtaining patient informed consent was granted by the Research Ethics Committee due to the health emergency presented by the COVID-19 pandemic.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first authors.
(noelia.diaz{at}vhebron.net)
(pgabriel{at}vhebron.net)
(martin.klammer{at}roche.com)
(rbarquin{at}vhebron.net)
(laura.castillo{at}vhebron.net)
(aesteban{at}vhebron.net)
(manhernan{at}vhebron.net)
(referrer{at}vhebron.net)
(tpumarola{at}vhebron.net)
Data availability statement updated.
Data Availability
The study was conducted in accordance with applicable regulations. Ethical approval was provided by the Research Ethics Committee for Drug Research of the Vall d'Hebron University Hospital (Barcelona, Spain). An exemption from obtaining patient informed consent was granted by the Research Ethics Committee due to the health emergency presented by the COVID-19 pandemic. Therefore, participants of this study did not give consent for their data to be shared with additional third parties. For more information on the study and data sharing, qualified researchers may contact the corresponding author Francisco Rodriguez-Frias (frarodri{at}gmail.com).
